title: Attention-Deficit Hyperactivity Disorder and Long-QT Syndrome: Risky Business.
authors.affiliation: Division of Cardiology, Children's National Medical Center, Washington, District of Columbia, USA.|Division of Cardiovascular Sciences, The National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Kaltman
authors.affiliation: Division of Cardiology, Children's National Medical Center, Washington, District of Columbia, USA.
authors.forename: Charles I
authors.initials: CI
authors.lastname: Berul
mesh_terms: D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000401:mortality*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008133:Long QT Syndrome / Q000401:mortality*; D008297:Male; D012042:Registries; D013575:Syncope / Q000401:mortality*
chemical_list: D000697:Central Nervous System Stimulants
keywords: adrenergic side effect; attention-deficit hyperactivity disorder; congenital arrhythmia; long-QT syndrome; stimulants